Area of research
Physiology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Asthma and respiratory diseases, Eosinophilic Disorders and Syndromes, Eosinophilic Esophagitis, and Inhalation and Respiratory Drug Delivery.
Prevention of Cardiovascular and Other Systemic Adverse Outcomes in Patients with Asthma Treated with Biologics
Anti-cytokine biologics for asthma in adults
International Severe Asthma Registry (ISAR): 2017–2024 Status and Progress Update
Allergic Fungal Rhinosinusitis Diagnosis, Management, Associated Conditions, Pathophysiology, and Future Directions: Summary of a Multidisciplinary Workshop
Current data on biologics: Evaluating clinical remission in asthma
Con: clinical remission in asthma – not yet there
Transient early blood eosinophil increases do not affect dupilumab’s long-term efficacy in patients with moderate-to-severe asthma
Choosing the Right Biologic for the Right Patient With Severe Asthma
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies
Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma
Real‐world biologics response and super‐response in the International Severe Asthma Registry cohort
What every clinician should know about inflammation in COPD
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study
Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthma
Biomarkers and clinical outcomes after tezepelumab cessation
Impact of Early Transient Increase in Eosinophil Count on the Long-term Efficacy of Dupilumab in Patients With Moderate-to-Severe Asthma: Liberty Asthma Traverse
Impact of early transient increase in eosinophils in patients with moderate-to-severe asthma on the long-term efficacy of dupilumab in TRAVERSE
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma
Are We Ready for Asthma Remission as a Clinical Outcome?
Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry
Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype
The Association Between Age at Diagnosis and Disease Characteristics and Damage in Patients With <scp>ANCA‐Associated</scp> Vasculitis
Association of Sputum Eosinophilia With Easily Measured Type-2 Inflammatory Biomarkers in Untreated Mild Persistent Asthma
Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma
Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma
How to design high quality acupuncture trials—a consensus informed by evidence
Ocular manifestations of ANCA-associated vasculitis
Urine eosinophil‐derived neurotoxin: A potential marker of activity in select eosinophilic disorders
Long-Term Efficacy of Dupilumab in Quadrants of Elevated- vs Low- Type 2 Biomarker Patients With Uncontrolled, Moderate-to-Severe Asthma: LIBERTY ASTHMA TRAVERSE